PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10469894-1	1999	As judged by findings in preclinical models, determinants of cellular sensitivity to cyclophosphamide and other oxazaphosphorines include two cytosolic aldehyde dehydrogenases, viz., ALDH1A1 and ALDH3A1.	oxazaphosphorines	112-129	aldehyde dehydrogenase 3 family member A1	Homo sapiens	195-202	
10856427-2	2000	Since resistance to oxazaphosphorines can be produced in mammalian cells by transfecting them with the gene for human ALDH isozyme 3 (hALDH3), it seems possible that patients receiving therapy for solid tumors with cyclophosphamide might be protected from myelosuppression by their prior transplantation with autologous bone marrow that has been transduced with a retroviral vector causing overexpression of hALDH3.	oxazaphosphorines	20-37	aldehyde dehydrogenase 3 family member A1	Homo sapiens	134-140	
10856427-2	2000	Since resistance to oxazaphosphorines can be produced in mammalian cells by transfecting them with the gene for human ALDH isozyme 3 (hALDH3), it seems possible that patients receiving therapy for solid tumors with cyclophosphamide might be protected from myelosuppression by their prior transplantation with autologous bone marrow that has been transduced with a retroviral vector causing overexpression of hALDH3.	oxazaphosphorines	20-37	aldehyde dehydrogenase 3 family member A1	Homo sapiens	408-414	
10856427-3	2000	We investigated whether retroviral introduction of hALDH3 into a human leukemia cell line confers resistance to oxazaphosphorines.	oxazaphosphorines	112-129	aldehyde dehydrogenase 3 family member A1	Homo sapiens	51-57	
10469894-2	1999	Each catalyzes the detoxification of the oxazaphosphorines; thus, cellular sensitivity to these agents decreases as cellular levels of ALDH1A1 and/or ALDH3A1 increase.	oxazaphosphorines	41-58	aldehyde dehydrogenase 3 family member A1	Homo sapiens	150-157	
11320670-3	2001	Preclinical models indicate that cellular sensitivity to cyclophosphamide and other oxazaphosphorines, e.g., ifosfamide, is inversely related to the cellular content of two aldehyde dehydrogenases, viz ALDH1A1 and ALDH3A1, and glutathione.	oxazaphosphorines	84-101	aldehyde dehydrogenase 3 family member A1	Homo sapiens	214-221	
24677340-9	2014	Thus, CB29 is a novel small molecule inhibitor of ALDH3A1, which might be useful as a chemical tool to delineate the role of ALDH3A1 in numerous metabolic pathways, including sensitizing ALDH3A1-positive cancer cells to oxazaphosphorines.	oxazaphosphorines	220-237	aldehyde dehydrogenase 3 family member A1	Homo sapiens	50-57	
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	oxazaphosphorines	376-393	aldehyde dehydrogenase 3 family member A1	Homo sapiens	44-50	
8654195-1	1995	The cytosolic class aldehyde dehydrogenase (ALDH-3) present in human normal tissues/secretions is apparently much less able to catalyze the oxidation aldophosphamide to carboxyphosphamide than is the ALDH-3 present in human tumor cells/tissues, suggesting that the former may be less able to protect cells from the cytotoxic action of cyclophosphamide, mafosfamide, and other oxazaphosphorines.	oxazaphosphorines	376-393	aldehyde dehydrogenase 3 family member A1	Homo sapiens	200-206	
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	130-136	
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193	
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193	
8654195-8	1995	These observations support the notions that 1) cellular sensitivity to the oxazaphosphorines decreases as the cellular content of ALDH-3 increases, 2) the foregoing is the consequence of ALDH-3-catalyzed oxidation (thus detoxification) of aldophosphamide, and 3) the ALDH-3 present in at least some tumor cells/tissues is a slight variant of the ALDH-3 present in normal tissues/secretions.	oxazaphosphorines	75-92	aldehyde dehydrogenase 3 family member A1	Homo sapiens	187-193	
11306049-1	2001	ALDH3A1 catalyzes the detoxification of cyclophosphamide, mafosfamide, 4-hydroperoxycyclophosphamide and other oxazaphosphorines.	oxazaphosphorines	111-128	aldehyde dehydrogenase 3 family member A1	Homo sapiens	0-7